Optimising obesity management: integrating continuous glucose monitoring with GLP-1 receptor agonists

IF 7.4 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes research and clinical practice Pub Date : 2025-08-21 DOI:10.1016/j.diabres.2025.112434

Pragati Gupta , Paolo Pozzilli

{"title":"Optimising obesity management: integrating continuous glucose monitoring with GLP-1 receptor agonists","authors":"Pragati Gupta , Paolo Pozzilli","doi":"10.1016/j.diabres.2025.112434","DOIUrl":null,"url":null,"abstract":"<div><div>Obesity management is evolving with the integration of digital and pharmacological innovations. Continuous Glucose Monitoring (CGM) offers dynamic insights into glucose variability, while glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, demonstrate potent weight loss and glycaemic control – even in non-diabetic populations. The synergy of CGM and GLP-1RAs enables personalised treatment by capturing real-time metabolic responses, with CGM offering behavioural feedback and GLP-1 RAs addressing hyperinsulinaemia and appetite dysregulation. Yet, no randomised controlled trials have assessed their combined use in obesity without diabetes, representing a critical evidence gap. Furthermore, CGM-derived metrics remain unstandardised in this context, limiting their interpretive value. Looking ahead, AI-driven CGM analysis could predict individual responsiveness to therapy, refining interventions and supporting long-term metabolic health. Together, these tools offer a promising path to breaking the cycle of insulin resistance and obesity.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"228 ","pages":"Article 112434"},"PeriodicalIF":7.4000,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822725004486","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Obesity management is evolving with the integration of digital and pharmacological innovations. Continuous Glucose Monitoring (CGM) offers dynamic insights into glucose variability, while glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, demonstrate potent weight loss and glycaemic control – even in non-diabetic populations. The synergy of CGM and GLP-1RAs enables personalised treatment by capturing real-time metabolic responses, with CGM offering behavioural feedback and GLP-1 RAs addressing hyperinsulinaemia and appetite dysregulation. Yet, no randomised controlled trials have assessed their combined use in obesity without diabetes, representing a critical evidence gap. Furthermore, CGM-derived metrics remain unstandardised in this context, limiting their interpretive value. Looking ahead, AI-driven CGM analysis could predict individual responsiveness to therapy, refining interventions and supporting long-term metabolic health. Together, these tools offer a promising path to breaking the cycle of insulin resistance and obesity.

查看原文本刊更多论文

优化肥胖管理：整合连续血糖监测与GLP-1受体激动剂

随着数字和药理学创新的融合，肥胖管理正在不断发展。连续血糖监测（CGM）提供了对葡萄糖变异性的动态洞察，而胰高血糖素样肽-1受体激动剂（GLP-1 RAs），如semaglutide，显示出有效的减肥和血糖控制-即使在非糖尿病人群中也是如此。CGM和GLP-1RAs的协同作用通过捕获实时代谢反应实现个性化治疗，CGM提供行为反馈，GLP-1RAs解决高胰岛素血症和食欲失调。然而，没有随机对照试验评估它们在肥胖无糖尿病患者中的联合使用，这代表了一个关键的证据缺口。此外，在这种情况下，cgm衍生的度量标准仍然没有标准化，限制了它们的解释价值。展望未来，人工智能驱动的CGM分析可以预测个体对治疗的反应性，改进干预措施并支持长期代谢健康。总之，这些工具为打破胰岛素抵抗和肥胖的恶性循环提供了一条有希望的途径。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes research and clinical practice 医学-内分泌学与代谢

CiteScore

10.30

自引率

3.90%

发文量

862

审稿时长

32 days

期刊介绍： Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.